In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 16_Supplement ( 2020-08-15), p. 4601-4601
Abstract:
Introduction: Early cancer detection remains a critical challenge to improve patients' survival rate and clinical outcomes. Alterations in DNA methylation play a key role in tumor initiation, development, progression and metastasis. Cell-free DNA (cfDNA) methylation analysis on liquid biopsies (e.g., blood and urine) holds a great promise for early detection of cancers even without symptoms. In this context, we are developing a non-invasive, cost-effective test that can detect several major cancer types, including lung (LnC), breast (BrC), colorectal (CRC), gastric (GC), esophageal (EC) and liver (LvC) cancers with high specificity (Sp) and sensitivity (Sn). These six cancer types represent two third of the newly diagnosed cancer patients and 72% of cancer deaths every year in China. Methods: In order to identify highly effective DNA methylation markers for early detection, we have conducted genome-wide methylation profiling on more than 2,000 benign and malignant tissue samples, including large number of early stage (Stage I/II) tumors and pre-cancerous lesions from lung, breast, colorectum, liver, stomach and esophagus. We then developed a high performance assay, Aurora, to capture cancer-specific DNA methylation signatures in plasma. Specifically, cfDNA was extracted from each of the plasma samples, bisulfite-converted, and analyzed by NGS on Illumina MiSeq system. Results and Discussion: To date, methylation profiles of plasma samples derived from, 1) 58 normal and 106 malignant pulmonary nodule patients, 2) 31 normal and 85 malignant CRC patients, and 3) 81 normal and 78 malignant breast nodule patients, were analyzed. Overall performances (Area Under Curve, AUC) of the Aurora test are 90%, 98% and 92% for LnC, BrC and CRC, respectively. Further clinical validation and evaluation are being conducted in larger independent cohorts of these three types of cancers as well as additional cohorts for the other cancers (GC, EC and LvC). The superior performance and low cost (~$100) make the Aurora test very promising for simultaneous screening of multiple major cancers in symptom-free, average risk populations. Citation Format: Linhao Xu, Jun Wang, Ting Yang, Jinsheng Tao, Xin Liu, Zhujia Ye, Dezhi Zhao, Zeyu Jiang, Zhiwei Chen, Jian-Bing Fan. Toward the development of a $100 screening test for 6 major cancer types [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4601.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2020-4601
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2020
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink
